medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 4

<< Back Next >>

Ann Hepatol 2015; 14 (4)

Comorbidities have a limited impact on post-transplant survival in carefully selected cirrhotic patients: a population-based cohort study

Cardoso FS, Bagshaw SM, Abraldes JG, Kneteman NM, Meeberg G, Fidalgo P, Karvellas CJ

Language: English
References: 39
Page: 505-514
PDF size: 157.23 Kb.


ABSTRACT

Background. Improving estimation of long-term survival of patients with end-stage liver disease after orthotopic liver transplantation (OLT) would optimize decisions on eligibility for transplant. We aimed to externally validate previously derived Charlson Comorbity Index for OLT (CCI-OLT); subsequently, we developed a new model to predict 5-year mortality after transplant. Material and methods. This single center retrospective cohort study included 524 consecutive adult cirrhotic patients who underwent OLT in 2002-2012. External validation of CCI-OLT used Kaplan-Meier method. Derivation of the new predictive model used Cox proportional hazards regression. Results. One-, 3-, and 5-year cumulative survival after OLT was 89%, 80%, and 73%, respectively. CCI-OLT was not associated with 5-year mortality after transplant (P = 0.34). We derived and internally validated a new predictive model of 5-year mortality after OLT based on six pre-transplant characteristics of patients: age, body mass index, hepatitis C, hepatic encephalopathy, intensive care unit stay at transplant, and live donor (C-index = 0.64). We further developed a nomogram to estimate individual probability of 1-, 3-, and 5-year survival after OLT. Conclusions. In our cohort, CCI-OLT was not associated with survival following transplant. The new predictive model discriminative capacity was only modest, suggesting that pre-transplant characteristics are of limited value in predicting post-transplant outcomes in thoroughly selected patients.


REFERENCES

  1. 1 Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology 2001; 120: 749-62.

  2. Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, Abu-Elmagd K, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232: 490-500.

  3. Duffy JP, Kao K, Ko CY, Farmer DG, McDiarmid SV, Hong JC, Venick RS, et al. Long-term patient outcome and quality of life after liver transplantation: analysis of 20-year survivors. Ann Surg 2010; 252: 652-61.

  4. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, Krom RA, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7: 567-80.

  5. Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol 2011; 54: 1297-306.

  6. Karvellas CJ, Lescot T, Goldberg P, Sharpe MD, Ronco JJ, Renner EL, Vahidy H, et al. Liver transplantation in the critically ill: a multicenter Canadian retrospective cohort study. Crit Care 2013; 17: R28.

  7. Merion RM. When is a patient too well and when is a patient too sick for a liver transplant? Liver Transpl 2004; 10: S69.

  8. Knight M, Barber K, Gimson A, Collett D, Neuberger J, Liver Advisory Group of National Health Service Blood Transplant. Implications of changing the minimal survival benefit in liver transplantation. Liver Transpl 2012; 18: 549-57.

  9. Thuluvath PJ, Yoo HY, Thompson RE. A model to predict survival at one month, one year, and five years after liver transplantation based on pretransplant clinical characteristics. Liver Transpl 2003; 9: 527-32.

  10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.

  11. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173: 676-82.

  12. Volk ML, Hernandez JC, Lok AS, Marrero JA. Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl 2007; 13: 1515-20.

  13. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335: 806-8.

  14. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-37.

  15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007; 30(Suppl. 1): S42-7.

  16. Arroyo V. Acute kidney injury (AKI) in cirrhosis: should we change current definition and diagnostic criteria of renal failure in chirrosis? J Hepatol 2013; 59(3): 415-7.

  17. Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. Biom J 2010; 52: 70-84.

  18. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. Stat Med 1984; 3: 143-52.

  19. Harrell FE, Jr. Regression Modelling Strategies. With Applications to Linear Models, Logistic Regression and Survival Analysis. New York: Springer; 2001.

  20. Schoening WN, Buescher N, Rademacher S, Andreou A, Kuehn S, Neuhaus R, Guckelberger O, et al. Twenty-Year Longitudinal Follow-Up After Orthotopic Liver Transplantation: A Single-Center Experience of 313 Consecutive Cases. Am J Transplant 2013; 13: 2384-94.

  21. Sela N, Croome KP, Chandok N, Marotta P, Wall W, Hernandez- Alejandro R. The changing donor characteristics in liver transplantation over the last 10 years in Canada. Liver Transpl 2013; 19: 1236-44.

  22. Rahimi RS, Rockey DC. End-stage liver disease complications. Curr Opin Gastroenterol 2013; 29: 257-63.

  23. Huo TI, Lin HC, Lee FY, Hou MC, Lee PC, Wu JC, Chang FY, et al. Occurrence of cirrhosis-related complications is a time-dependent prognostic predictor independent of baseline model for end-stage liver disease score. Liver Int 2006; 26: 55-61.

  24. Coombes JM, Trotter JF. Development of the allocation system for deceased donor liver transplantation. Clin Med Res 2005; 3: 87-92.

  25. Murray KF, Carithers RL, Jr. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-32.

  26. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, Greenstein SM, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-90.

  27. Freire MP, Soares OIC, Bonazzi PR, Guimarães T, Ramos FER, Bacchella T, Costa SF, et al. Surgical site infections in liver transplant recipients in the model for end-stage liver disease era: An analysis of the epidemiology, risk factors, and outcomes. Liver Transpl 2013; 19: 1011-9.

  28. Barbier L, Garcia S, Cros J, Borentain P, Botta-Fridlund D, Paradis V, Le Treut YP, et al. Assessment of Chronic Rejection in Liver Graft Recipients Receiving Immunosuppression with low-Dose Calcineurin Inhibitors. J Hepatol 2013; 59: 1223-30.

  29. O’Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology 2008; 134: 1764-76.

  30. Collins BH, Pirsch JD, Becker YT, Hanaway MJ, Van der Werf WJ, D’Alessandro AM, Knechtle SJ, et al. Long-term results of liver transplantation in older patients 60 years of age and older. Transplantation 2000; 70: 780-3.

  31. Wong RJ, Gish RG, Cheung R, Ahmed A. Pre-Transplant Hepatic Encephalopathy is Associated with Significantly Lower Survival Following Liver Transplantation. Hepatology 2014; 60(4): 392A.

  32. Kanwal F, Chen D, Ting L, Gornbein J, Saab S, Durazo F, Yersiz H, et al. A model to predict the development of mental status changes of unclear cause after liver transplantation. Liver Transpl 2003; 9: 1312-9.

  33. Sotil EU, Gottstein J, Ayala E, Randolph C, Blei AT. Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl 2009; 15: 184-92.

  34. Dutkowski P, Oberkofler CE, Slankamenac K, Puhan MA, Schadde E, Müllhaupt B, Geier A, et al. Are there better guidelines for allocation in liver transplantation? A novel score targetting justice and utility in the model for endstage liver disease era. Ann Surg 2011; 254(5): 745-53.

  35. Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, García-Valdecasas JC, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39(3): 389-96.

  36. Lens S, Gambato M, Londoño MC, Forns X. Interferon-free regimens in the liver-transplant setting. Semin Liver Dis 2014; 34: 58-71.

  37. Gane EJ, Agarwal K. Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: “A Flood of Opportunity”. Am J Transplant 2014; 14: 994-1002.

  38. Kasahara M, Umeshita K, Inomata Y, Uemoto S; Japanese Liver Transplantation Society. Long-term outcomes of pediatric living donor liver transplantation in Japan: an analysis of more than 2200 cases listed in the registry of the Japanese Liver Transplantation Society. Am J Transplant 2013; 13: 1830-9.

  39. Reichman TW, Katchman H, Tanaka T, Greig PD, McGilvray ID, Cattral MS, Renner EL, et al. Living donor versus deceased donor liver transplantation: a surgeon-matched comparison of recipient morbidity and outcomes. Transpl Int 2013; 26: 780-7.




2020     |     www.medigraphic.com